Brief: Altamira Therapeutics Continue Bentrio Clinical Trial For Seasonal Allergic Rhinitis In Australia
03/10/2022 14:07
Oct 3 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS CONTINUE BENTRIO CLINICAL TRIAL FOR
SEASONAL ALLERGIC RHINITIS IN AUSTRALIA
* ALTAMIRA THERAPEUTICS LTD - EXPECT NASAR STUDY TO
REINFORCE AND
COMPLEMENT EARLIER FINDINGS, WITH ITS DATA READ-OUT ANTICIPATED
IN Q1 OF 2023
Source text for Eikon: ID:nGNX66xXnC
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering